Package: CFO 2.2.0

Jialu Fang

CFO: CFO-Type Designs in Phase I/II Clinical Trials

In phase I clinical trials, the primary objective is to ascertain the maximum tolerated dose (MTD) corresponding to a specified target toxicity rate. The subsequent phase II trials are designed to examine the potential efficacy of the drug based on the MTD obtained from the phase I trials, with the aim of identifying the optimal biological dose (OBD). The 'CFO' package facilitates the implementation of dose-finding trials by utilizing calibration-free odds type (CFO-type) designs. Specifically, it encompasses the calibration-free odds (CFO) (Jin and Yin (2022) <doi:10.1177/09622802221079353>), randomized CFO (rCFO), precision CFO (pCFO), two-dimensional CFO (2dCFO) (Wang et al. (2023) <doi:10.3389/fonc.2023.1294258>), time-to-event CFO (TITE-CFO) (Jin and Yin (2023) <doi:10.1002/pst.2304>), fractional CFO (fCFO), accumulative CFO (aCFO), TITE-aCFO, and f-aCFO (Fang and Yin (2024) <doi:10.1002/sim.10127>). It supports phase I/II trials for the CFO design and only phase I trials for the other CFO-type designs. The ‘CFO' package accommodates diverse CFO-type designs, allowing users to tailor the approach based on factors such as dose information inclusion, handling of late-onset toxicity, and the nature of the target drug (single-drug or drug-combination). The functionalities embedded in 'CFO' package include the determination of the dose level for the next cohort, the selection of the MTD for a real trial, and the execution of single or multiple simulations to obtain operating characteristics. Moreover, these functions are equipped with early stopping and dose elimination rules to address safety considerations. Users have the flexibility to choose different distributions, thresholds, and cohort sizes among others for their specific needs. The output of the 'CFO' package can be summary statistics as well as various plots for better visualization. An interactive web application for CFO is available at the provided URL.

Authors:Jialu Fang [aut, cre], Ninghao Zhang [aut], Wenliang Wang [aut], Guosheng Yin [aut]

CFO_2.2.0.tar.gz
CFO_2.2.0.tar.gz(r-4.5-noble)CFO_2.2.0.tar.gz(r-4.4-noble)
CFO_2.2.0.tgz(r-4.4-emscripten)CFO_2.2.0.tgz(r-4.3-emscripten)
CFO.pdf |CFO.html
CFO/json (API)

# Install 'CFO' in R:
install.packages('CFO', repos = c('https://cran.r-universe.dev', 'https://cloud.r-project.org'))

Peer review:

This package does not link to any Github/Gitlab/R-forge repository. No issue tracker or development information is available.

1.90 score 568 downloads 18 exports 34 dependencies

Last updated 1 months agofrom:64f35b5896. Checks:OK: 2. Indexed: yes.

TargetResultDate
Doc / VignettesOKDec 16 2024
R-4.5-linuxOKDec 16 2024

Exports:aCFO.nextCFO.nextCFO.ocCFO.selectmtdCFO.simuCFO2d.nextCFO2d.ocCFO2d.selectmtdCFO2d.simuCFOeff.nextCFOeff.ocCFOeff.selectobdCFOeff.simugammatablelateonset.nextlateonset.simupCFO.nextrCFO.next

Dependencies:clicolorspacedplyrfansifarvergenericsggplot2gluegtableIsoisobandlabelinglatticelifecyclemagrittrMASSMatrixmgcvmunsellnlmepbapplypillarpkgconfigR6RColorBrewerrlangscalessurvivaltibbletidyselectutf8vctrsviridisLitewithr

Readme and manuals

Help Manual

Help pageTopics
Determination of the dose level for next cohort in the accumulative calibration-free odds (aCFO) design for phase I trialsaCFO.next
Determination of the dose level for next cohort in the calibration-free odds (CFO) design for phase I trialsCFO.next
Generate operating characteristics of phase I trials single-drug trials in multiple simulationsCFO.oc
Select the maximum tolerated dose (MTD) for the real single-drug trialsCFO.selectmtd
Conduct one simulation using the calibration-free odds (CFO), accumulative CFO (aCFO) design, or randomized CFO (rCFO) design for phase I trials.CFO.simu
Determinate the dose level for the next cohort in the two-dimensional calibration-free odds (2dCFO) design for phase I trials.CFO2d.next
Generate operating characteristics of phase I drug-combination trials in multiple simulationsCFO2d.oc
Select the maximum tolerated dose (MTD) for the real drug combination trialsCFO2d.selectmtd
Conduct one simulation using the two-dimensional calibration-free odds (2dCFO) design for phase I trials.CFO2d.simu
Determination of the dose level for next cohort in the calibration-free odds (CFO) design for phase I/II trialsCFOeff.next
Generate operating characteristics of phase I/II trials single-drug trials in multiple simulations.CFOeff.oc
Select the optimal biological dose (OBD) for the real single-drug trialsCFOeff.selectobd
Conduct one simulation using the calibration-free odds (CFO) design for phase I/II trialsCFOeff.simu
Generating table of threshold gamma_L and gamma_R in the calibration-free odds (CFO) designgammatable
Determination of the dose level for next cohort in the calibration-free odds type (CFO-type) design with late-onset toxicity for phase I trialslateonset.next
Conduct one simulation using the calibration-free odds type (CFO-type) design with late-onset toxicity for phase I trials.lateonset.simu
Determination of the dose level for next cohort in the precision calibration-free odds (pCFO) design for phase I trialspCFO.next
Plot the results by other functionsplot.cfo
Generate descriptive summary for objects returned by other functionsprint.cfo
Determination of the dose level for next cohort in the randomized calibration-free odds (rCFO) design for phase I trialsrCFO.next
Generate descriptive summary for objects returned by other functionssummary.cfo